Rigel Pharmaceuticals RIGL Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Rigel Pharmaceuticals's change in AR?
- Rigel Pharmaceuticals (RIGL) reported change in AR of -$1.82M in Q1 2026.
- How has Rigel Pharmaceuticals's change in AR changed year-over-year?
- Rigel Pharmaceuticals's change in AR decreased by 2573.5% year-over-year, from -$68K to -$1.82M.
- What is the long-term trend for Rigel Pharmaceuticals's change in AR?
- Over 2 years (2022 to 2025), Rigel Pharmaceuticals's change in AR has grown at a -38.1% compound annual growth rate (CAGR), from $26.52M to $10.15M.
- What does change in AR mean?
- Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.